Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Lagging Indicators": Is There A "Drug Lag" Between U.S. And Europe?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's John Jenkins discusses concerns about return of the "drug lag" during IoM meeting on drug safety.

You may also be interested in...



Comparing EU Vs. US Accelerated Pathway Approval Times Makes Senior UK Regulator 'Slightly Defensive'

Record-setting US Blincyto approval is case in point for discussion; EMA/MHRA official Robert Hemmings says EU review structure taps into expertise from "the whole of the continent," plus rapporteurs' independent views.

Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol

FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.

Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol

FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel